Skip to content
Menu

Top 3 Health Care Stocks That May Collapse This Month

Avi Kapoor 1 day ago

MarketsTrading IdeasPre-Market OutlookShort IdeasNews

Three healthcare stocks flash overbought warnings: Surgery Partners (RSI 89.5), Mentari Therapeutics (85.2), and Xeris Biopharma (71.3).

As of Nov. 16, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here’s the latest list of major overbought players in this sector.

Surgery Partners Inc (NASDAQ:SGRY)

  • On Nov. 9, Surgery Partners posted third-quarter adjusted earnings of 16 cents per share, up from 13 cents per share in the year-ago period. Eric Evans, Chief Executive Officer, said, “Our financial results in the third quarter reflect the impact of the successful Idaho Falls divestiture and sustained momentum in our core business, underscoring the value of our short-stay surgical platform.” The company’s stock gained around 82% over the past month and has a 52-week high of $27.22.
  • RSI Value: 89.5                                
  • SGRY Price Action: Shares of Surgery Partners gained 1.4% to close at $26.95 on Friday.
  • Edge Stock Ratings: 98.58 Momentum score with Value at 34.58.

Mentari Therapeutics, Inc. (NASDAQ:MTRI)

  • On Nov. 13, Wedbush analyst Laura Chico initiated coverage on Mentari Therapeutics with an Outperform rating and announced a price target of $33. The company’s stock gained around 40% over the past month and has a 52-week high of $20.00.
  • RSI Value: 85.2
  • MTRI Price Action: Shares of Mentari Therapeutics gained 1.4% to close at $18.60 on Friday.

Xeris Biopharma Holdings Inc (NASDAQ:XERS)

  • On Nov. 5, Xeris Biopharma reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates. “As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030,” said John Shannon, Chairman and Chief Executive Officer of Xeris. The company’s stock gained around 65% over the past month and has a 52-week high of $16.88.
  • RSI Value: 71.3                                                                                                    
  • XERS Price Action: Shares of Xeris Biopharma gained 0.1% to close at $16.66 on Friday.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock

Read at benzinga.com